Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL

Publish date:: December 10, 2020

Key clinical point: The novel bispecific antibody odronextamab (REGN1979) demonstrated durable responses and acceptable safety in a phase 1 study of patients with highly refractory B-cell non-Hodgkin lymphoma.

Major finding: Complete responses were durable in 80% or more of patients, with acceptable levels of cytokine release syndrome and neurotoxicity.

Study details: Updated analysis of a phase 1 study including 136 patients with B-cell NHLs who had received at least two prior lines of systemic therapy.

Disclosures: Dr. Bannerji reported research funding from Regeneron Pharmaceuticals, which sponsored the study, and other pharmaceutical companies. Dr. Bannerji’s spouse is an employee of Sanofi-Pasteur.

Citation:

Bannerji R et al. ASH 2020, Abstract 400.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,